The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers.
 
Rutika Mehta
Honoraria - Bristol-Myers Squibb; Lilly; NCCN; Pfizer/EMD Serono (I); Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Taiho Pharmaceutical
Speakers' Bureau - Natera
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Sarbajit Mukherjee
Research Funding - Ipsen (Inst)
Travel, Accommodations, Expenses - Nouscom (Inst)
 
Kelsey Klute
Consulting or Advisory Role - Cancer Expert Now
Research Funding - AstraZeneca (Inst); FibroGen (Inst)
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences
 
Uqba Khan
Honoraria - Cardinal Health
Travel, Accommodations, Expenses - Cardinal Health; Conquer Cancer Foundation
 
Sahrish Khan
No Relationships to Disclose
 
Carina Puello
No Relationships to Disclose
 
Sabrina Machado
No Relationships to Disclose
 
Paul J. Christos
No Relationships to Disclose
 
Nicholas J. Sanfilippo
Stock and Other Ownership Interests - Oncodisc
 
Manish A. Shah
Consulting or Advisory Role - Astellas Pharma; Lilly Japan
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Oncolys BioPharma (Inst)